Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

BACKGROUND: In recent years, PD-1/PD-L1 immune checkpoint inhibitors have improved cancer therapy in many tumor types, but no benefit of immune checkpoint therapy has been found in glioblastoma multiforme (GBM). Based on the results of our earlier work, which showed a reduction of PD-L1 expression i...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BMC Cancer
Main Authors: Heynckes, Sabrina, Daka, Karam, Franco, Pamela, Gaebelein, Annette, Frenking, Jan Hendrik, Doria-Medina, Roberto, Mader, Irina, Delev, Daniel, Schnell, Oliver, Heiland, Dieter Henrik
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6359796/
https://ncbi.nlm.nih.gov/pubmed/30709339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5308-y
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki